These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection. Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152 [No Abstract] [Full Text] [Related]
24. [Profile of antifungal susceptibility of species of Candida isolated from hemocultures in a university hospital, Maracaibo, Venezuela]. Arcaya NM; Mesa LM; Pineda MR; Beltrán-Luengo H; Milagros Calvo B Rev Iberoam Micol; 2006 Jun; 23(2):97-100. PubMed ID: 16854186 [TBL] [Abstract][Full Text] [Related]
25. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis. Jandourek A; Brown P; Vazquez JA Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825 [No Abstract] [Full Text] [Related]
26. Identification of an amphotericin B resistant strain of Candida albicans using a rapid 3H-glucose incorporation microassay. Sweeney JF; Greene JN; Hiemenz JW; Wei S; Rosemurgy AS; Djeu JY J Infect; 1996 Nov; 33(3):221-6. PubMed ID: 8945714 [TBL] [Abstract][Full Text] [Related]
27. Assessment of the Li J; Coste AT; Bachmann D; Sanglard D; Lamoth F Microbiol Spectr; 2021 Dec; 9(3):e0139521. PubMed ID: 34730380 [TBL] [Abstract][Full Text] [Related]
28. Distribution and susceptibility to amphotericin B and fluconazole of Candida spp. isolated from Taiwan. Yang YL; Ho YA; Cheng HH; Lo HJ; Epidemiol Infect; 2005 Apr; 133(2):325-30. PubMed ID: 15816158 [TBL] [Abstract][Full Text] [Related]
29. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Clancy CJ; Nguyen MH Antimicrob Agents Chemother; 1999 May; 43(5):1289-90. PubMed ID: 10223955 [TBL] [Abstract][Full Text] [Related]
30. Containment strategies to address the expanding threat of multidrug-resistant Candida auris. McCarthy MW; Walsh TJ Expert Rev Anti Infect Ther; 2017 Dec; 15(12):1095-1099. PubMed ID: 29110544 [TBL] [Abstract][Full Text] [Related]
31. Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris. Dudiuk C; Berrio I; Leonardelli F; Morales-Lopez S; Theill L; Macedo D; Yesid-Rodriguez J; Salcedo S; Marin A; Gamarra S; Garcia-Effron G J Antimicrob Chemother; 2019 Aug; 74(8):2295-2302. PubMed ID: 31081031 [TBL] [Abstract][Full Text] [Related]
32. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780 [TBL] [Abstract][Full Text] [Related]
33. Comparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris. Shivarathri R; Jenull S; Chauhan M; Singh A; Mazumdar R; Chowdhary A; Kuchler K; Chauhan N Antimicrob Agents Chemother; 2022 Jun; 66(6):e0227621. PubMed ID: 35652307 [TBL] [Abstract][Full Text] [Related]
34. Candida auris Clinical Isolates from South Korea: Identification, Antifungal Susceptibility, and Genotyping. Kwon YJ; Shin JH; Byun SA; Choi MJ; Won EJ; Lee D; Lee SY; Chun S; Lee JH; Choi HJ; Kee SJ; Kim SH; Shin MG J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728190 [No Abstract] [Full Text] [Related]
35. Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. Arendrup MC; Prakash A; Meletiadis J; Sharma C; Chowdhary A Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416539 [No Abstract] [Full Text] [Related]
36. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. Anaissie EJ; Karyotakis NC; Hachem R; Dignani MC; Rex JH; Paetznick V J Infect Dis; 1994 Aug; 170(2):384-9. PubMed ID: 8035024 [TBL] [Abstract][Full Text] [Related]
37. [Current candidiasis topics: monitoring Liposomal amphotericin B using candidiasis flow charts (discussion)]. Takesue Y Jpn J Antibiot; 2012 Apr; 65(2):111-9. PubMed ID: 22970634 [No Abstract] [Full Text] [Related]
38. Amphotericin B and fluconazole susceptibility of Candida species determined by cell-chip technology. Bouquet O; Kocsis B; Kilár F; Lóránd T; Kustos I Mycoses; 2012 May; 55(3):e90-6. PubMed ID: 22035475 [TBL] [Abstract][Full Text] [Related]
39. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178 [TBL] [Abstract][Full Text] [Related]
40. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey. Dagi HT; Findik D; Senkeles C; Arslan U Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]